SHIONOGI Aktie

 

Ahead of the 2026 U.S. Conference on HIV/AIDS (USCHA), ViiV Healthcare announced it has funded 230 community-based organizations this year to strengthen essential HIV services and help connect people to HIV prevention and care DURHAM, N.C.--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced more than $33 million in U.S. community grants awarded in 2026. These investments support 230 community-based organizations in 110 cities across 36 states and territories, including Puerto Rico, working to ensure that people and communities most disproportionately impacted by HIV have access to the support they need. The grants, which were awarded as part of ViiV's Positive Action program, are supporting community-driven solutions to address urgent needs and ensure sustained delivery of essential HIV prevention and care services on the frontlines of the HIV response. The funding helps local organizations connect people to care, red...

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that the Biomedical Advanced Research and Development Authority (BARDA) has exercised a $36.9 million procurement option, under Project BioShield funding, from its April 2026 contract with Shionogi Inc., a New Jersey-based subsidiary of Shionogi, to procure Fetroja® (cefiderocol) as a critical countermeasure against difficult-to-treat Gram-negative bacterial infections and pathogens that present a high-priority biothreat to national health security. The order exercises the first of several procurement and related options under the contract, with initial funding of $119 million and multiyear options for a total of up to $482 million. Other projects under the contract include establishing a U.S. drug product manufacturing site for Fetroja, advancing Fetroja for the treatment of infections caused by high-priority biothreat pathogens and exp...

The pharmaceutical manufacturer wants to accelerate its overseas growth while broadening its portfolio beyond its traditional strength in infectious disease medications....

Isao Teshirogi, President and CEO of Shionogi & Co said the company is eyeing more manufacturing sites in the US for next decade. 'We're actively pursuing minimum three deals today', he shared in an exclusive conversation with Bloomberg's Lisa Du. (Source: Bloomberg)...

Shionogi & Co. is actively pursuing at least three acquisition opportunities and considering expanding US manufacturing capacity, as the Japanese drugmaker seeks to diversify its production base and geopolitical risk over the next decade....

Shionogi & Co. (SGIOY) delivered earnings and revenue surprises of +100.00% and -0.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

TOKYO (dpa-AFX) - Shionogi & Co., Ltd. (SGIOF) announced a profit for its first quarter that Increased, from the same period last yearThe company's bottom line came in at JPY97.696 billion, or JPY......

Shionogi & Co. (SGIOY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

Apnimed Inc. filed for a US initial public offering, as its oral drug to treat obstructive sleep apnea moves closer to being commercialized....

QBTS expands into AI and blockchain via a live quantum-classical testNet with Postquant Labs and early drug discovery gains with Shionogi....

Shionogi & Co.'s experimental Covid-19 pill cut the risk of infection among people exposed to the disease at home, according to a study that could revive interest in antivirals as a preventive tool....

TOKYO (dpa-AFX) - Shionogi & Co., Ltd. (SGIOF) revealed earnings for its full year that Increased, from last yearThe company's bottom line totaled JPY205.159 billion, or JPY241.04 per share. This ......

Tanabe Pharma America Remains Focused on Rare Disease Innovation and Addressing Unmet Patient Needs JERSEY CITY, N.J., April 1, 2026 /PRNewswire/ -- Tanabe Pharma America, Inc. (TPA), the wholly owned subsidiary of Tanabe Pharma Corporation, today announced the finalization of the......

 Integration Fully Operational on Day One to Ensure Continuity of Care for the ALS Community With More than 100 Team Members Joining Shionogi from Tanabe Pharma America Acquisition Establishes a Strong Commercial Platform in Rare Disease to Support Future LaunchesOSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced that we have completed the transfer of all rights for RADICAVA (edaravone), including intellectual property rights and sales rights, in major countries and regions to our company from Tanabe Pharma Corporation. Transfer of rights in additional countries and regions is forthcoming. The acquisition and integration of RADICAVA team members, programs and platforms adds to ongoing strategic investments in rare disease and establishes Shionogi as a commercially viable rare disease company ready to introduce new treatments to patients with unmet medical needs. RADICAVA is approved by the U.S...

GSK PLC and Shionogi & Co Ltd on Wednesday said the replacement of Pfizer Inc's stake in the ViiV Healthcare Ltd joint...

NEW YORK CITY (dpa-AFX) - GSK plc (GSK, GSK.L), and Shionogi & Co. announced the completion of the transaction for the 11.7% economic interest in ViiV Healthcare previously held by Pfizer (PFE) to......

Das Instrument SH0 JP3347200002 SHIONOGI + CO. LTD EQUITY wird ex Dividende/Zinsen gehandelt am 30.03.2026 The instrument SH0 JP3347200002 SHIONOGI + CO. LTD EQUITY has its ex-dividend/interest day on 30.03.2026...

The invasive fungal infections market is expected to grow by 2034, owing to the approval of new agents such as Ibrexafungerp (Glaxosmithkline/SCYNEXIS), Fosmanogepix (Basilea Pharmaceutica), Olorofim (F901318) (Shionogi/F2G), Opelconazole (PC945) (Pulmocide), and others in frontline and......

WEST CHESTER, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced the launch of YCANTH® in Japan by its partner, Torii Pharmaceutical Co. Ltd. (“Torii”), a wholly-owned subsidiary of Shionogi & Co., Ltd., for the treatment of molluscum contagiosum (“molluscum”)....